The central problem the researchers set out to solve is one of incomplete explanation. Pathogenic or likely pathogenic variants in sarcomere-encoding genes, the category the team abbreviates as SARC-HCM-P/LP, account for only about one-third of hypertrophic cardiomyopathy cases. The remaining majority of patients have no detectable single-gene culprit, and even among confirmed carriers, the condition displays notoriously variable penetrance: some people harboring a dangerous variant develop severe disease early in life, while others reach old age with hearts that function normally. This uneven expressivity has long hinted that something beyond the rare variant itself, most plausibly the cumulative influence of thousands of common genetic variants scattered across the genome, helps determine who actually becomes ill and how sick they become.

Earlier attempts to capture that polygenic contribution ran into a stubborn equity problem. Existing polygenic risk scores for hypertrophic cardiomyopathy were built almost exclusively from genome-wide association studies of European-ancestry populations, and when applied to individuals of African, East Asian, Hispanic, or other ancestries, their predictive performance deteriorated sharply. This limitation mirrors a broader and well-documented weakness of genomics: because most large genetic datasets over-represent people of European descent, risk scores trained on them often fail the very populations that already bear disproportionate burdens of cardiovascular disease and face greater barriers to genetic diagnosis. The new study was designed from the ground up to confront that disparity rather than treat it as an afterthought.

To construct the score, the team drew on genome-wide association summary statistics from three complementary sources: the BioBank Japan, the Million Veteran Program, and a meta-analysis of seven European-ancestry cohorts. By combining association signals from Japanese, multiethnic American, and European datasets, the investigators built a score intended to capture disease-relevant variants across the genetic ancestry continuum rather than within a single population. The statistical machinery behind such scores involves weighting millions of single nucleotide polymorphisms according to their measured association with disease risk, then summing those weighted contributions for each individual to yield a single number representing inherited polygenic susceptibility. Methods of this kind, including Bayesian shrinkage approaches refined in recent years, allow researchers to distill a usable clinical signal from noisy, genome-scale data while guarding against overfitting.

The validation stage took place in a genuinely diverse national cohort: participants in the United States-based All of Us Research Program, one of the largest and most ancestrally diverse biomedical datasets ever assembled. The results were unambiguous. Individuals whose polygenic score placed them in the top quintile of the population had a 2.11-fold increased risk of developing hypertrophic cardiomyopathy compared with the rest of the population. That effect size, for a common-variant composite score alone, is clinically meaningful and rivals the discriminatory power that polygenic scores have achieved for more common conditions such as coronary artery disease. The score also improved overall risk stratification and showed trends toward improved ancestry-specific prediction, suggesting that the multiancestry training strategy partially, if not perfectly, mitigated the performance cliff that plagues European-derived scores.

The most striking finding, however, emerged when the researchers layered the polygenic score on top of the rare-variant picture. Among carriers of pathogenic or likely pathogenic sarcomere variants, individuals in the highest polygenic score quintile faced nearly a seventy-fold higher risk of actually developing hypertrophic cardiomyopathy compared with low-scoring counterparts. This is precisely the kind of result that cardiologists and genetic counselors have been waiting for. Variable penetrance among variant carriers has made counseling agonizingly uncertain: telling a young person they carry a disease-causing mutation without being able to say whether that mutation will ever manifest is of limited clinical use. A polygenic measure that helps distinguish the carriers likely to develop disease from those likely to remain unaffected converts a static genetic diagnosis into a dynamically graded risk estimate.

Beyond prediction of who develops disease, the score carried prognostic weight. Among individuals already diagnosed with hypertrophic cardiomyopathy, a higher polygenic score was associated with adverse cardiovascular outcomes, indicating that the same aggregate burden of common variants that raises disease susceptibility also shapes disease severity and trajectory. This suggests that polygenic information could eventually inform not only screening decisions but also surveillance intensity and management priorities for diagnosed patients. Extended analyses reinforced the pattern: among carriers of predicted deleterious variants, disease prevalence rose steadily across polygenic score quintiles, with the highest quintile showing roughly 2.4-fold higher penetrance than the lowest, and hazard ratios climbing in a graded fashion as score category increased.

The technical infrastructure supporting the study reflects the maturing standards of the polygenic risk score field. The investigators performed careful quality control, addressed the statistical pitfall known as Winner’s Curse that inflates effect estimates in discovery samples, and evaluated performance using measures including odds ratios per standard deviation of score change and area under the receiver operating characteristic curve across ancestry groups. In a notable commitment to transparency and reproducibility, the team made its analysis code publicly available on GitHub and deposited the underlying genome-wide association summary statistics in the GWAS Catalog, enabling other researchers to replicate, extend, or adapt the score for their own populations. Individual-level participant data remain accessible through the All of Us Researcher Workbench under its data use agreements.

The clinical implications reach well beyond hypertrophic cardiomopathy itself. Hypertrophic cardiomyopathy affects roughly one in several hundred people and remains a leading cause of sudden cardiac death in young athletes, yet many cases go undiagnosed until a catastrophic event occurs. A validated, ancestry-fair risk score could be deployed to flag individuals who warrant echocardiographic screening, genetic testing, or closer longitudinal follow-up, potentially catching disease before it strikes. For gene-positive family members of affected patients, combining sarcomere variant status with a polygenic score could personalize the schedule of cardiac imaging and the timing of preventive interventions, including the newer generation of cardiac myosin inhibitors that have transformed pharmacologic management of the disease.

The authors and observers of the field alike caution that scores of this kind are not yet ready to replace clinical judgment or guideline-based testing. The ancestry-specific performance gains, while encouraging, remained trends rather than definitive demonstrations, and further validation in independent, prospective cohorts will be essential before polygenic information enters routine cardiology practice. Questions about how best to communicate a seventy-fold relative risk to a worried variant carrier, and how insurers and employers might use such information, also demand careful attention. Still, the study marks a turning point: it demonstrates that the variable penetrance puzzle of hypertrophic cardiomyopathy is, at least in part, quantitatively solvable, and that the solution can be built to serve populations of all ancestries rather than a genetically privileged few. As multiancestry genomic resources continue to grow, the integration of rare variant status and polygenic background promises to become a standard pillar of precision cardiovascular medicine, reshaping how inherited heart disease is predicted, counseled, and ultimately prevented.

Subject of Research: Development and validation of a multiancestry polygenic risk score for hypertrophic cardiomyopathy risk stratification

Article Title: A multiancestry polygenic risk score improves stratification in patients with hypertrophic cardiomyopathy

Article References: Bal, H. S., Pampana, A., Nayak, A., Gaonkar, M., Patel, S., Yerabolu, K., Vekariya, N., Patel, N., Kalra, R., Li, P., Arora, G., & Arora, P. (2026). A multiancestry polygenic risk score improves stratification in patients with hypertrophic cardiomyopathy. Nature Cardiovascular Research, 5(9), 891-903. https://doi.org/10.1038/s44161-026-00866-8

Image Credits: AI Generated

DOI: 10.1038/s44161-026-00866-8

Keywords: hypertrophic cardiomyopathy, polygenic risk score, multi-ancestry genomics, sarcomere variants, variable penetrance, All of Us Research Program, cardiovascular genetics, risk stratification, precision medicine, genome-wide association study, genetic counseling, sudden cardiac death